Price (delayed)
$2.66
Market cap
$148.72M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.28
Enterprise value
$103.8M
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.
There are no recent dividends present for SPRO.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.